Biomedical applications of 10B and 11B NMR

NMR in Biomedicine

Volumn 18, Issue 2, 2005, Pages 74-82

  Bendel, Peter ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

10B NMR; 11B NMR; BNCT; BPA; BSH; MRI

Indexed keywords

BORON; CELLS; MAGNETIC RESONANCE IMAGING; METABOLISM; MOLECULES; NEUTRONS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT TREATMENT; PHARMACOKINETICS; RADIATION; TISSUE;

BINARY RADIATION; BIOMEDICAL APPLICATIONS; BORON NEUTRON CAPTURE THERAPY (BCNT); EPITHERMAL NEUTRONS;

BIOMEDICAL ENGINEERING;

BORON; BORON 10; ISOTOPE; PROTON; BORON DERIVATIVE;

CELL CULTURE; CELL DAMAGE; DRUG METABOLISM; EXPERIMENTAL ANIMAL; HUMAN; IN VIVO STUDY; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOMEDICAL ENGINEERING; COMPUTER ASSISTED RADIOTHERAPY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; RADIATION DOSE; RADIOMETRY; TISSUE DISTRIBUTION;

ANIMALIA;

ANIMALS; BIOMEDICAL ENGINEERING; BORON; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; HUMANS; ISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; METABOLIC CLEARANCE RATE; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TISSUE DISTRIBUTION;

EID: 17344363016     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.886     Document Type: Review

References (47)

1. Dembitsky VM, Smoum R, Al-Quntar AA, Abu Ali H, Pergament I, Srebnik M. Natural occurrence of boron-containing compounds in plants, algae and microorganisms. Plant Sci. 2002; 163: 931-942.
2. 11B Nuclear magnetic resonance studies of the structure of the transition state analogue phenylboronic acid bound to chymotrypsin. J. Am. Chem. Soc. 1988; 110: 309-310.
3. 11B NMR evidence for specific binding of borate ion to cytochrome c. Inorg. Chim. Acta 1998; 273: 388-392.
4. Taler G, Eliav U, Navon G. Detection and characterization of boric acid and borate ion binding to cytochrome c using multiple quantum filtered NMR. J. Magn. Res. 1999; 141: 228-238.
5. Sauerwein W. Principles and history of neutron capture therapy. Strahenther. Onkol. 1993; 1: 1-6.
6. Barth RF, Soloway AH, Brugger RM. Boron neutron capture therapy of brain tumors: past history, current status, and future potential. Clin. Sci. Rev. 1996; 14: 534-550.
7. Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG. The chemistry of neutron capture therapy. Chem. Rev. 1998; 98: 1515-1562.
8. Barth RF, Soloway AH, Goodman JH, Gahbauer RA, Gupta N, Blue TE, Yang W, Tjarks W. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality. Neurosurgery 1999; 44: 433-451.
9. Barth RF. A critical assessment of boron neutron capture therapy: an overview. J. Neuro-oncol. 2003; 62: 1-5.
10. Nakagawa Y, Pooh K, Kobayashi T, Kageji T, Uyama S, Matsumura A, Kumada H. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J. Neuro-oncol. 2003; 62: 87-99.
11. Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J. Neuro-oncol. 2003; 62: 101-109.
12. Busse PM, Harling OK, Palmer MR, Kiger WS, Kaplan J, Kaplan I, Chuang CF, Goorley JT, Riley KJ, Newton TH, Santa Cruz GA, Lu X, Zamenhof RG. A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J. Neuro-oncol. 2003; 62: 111-121.
13. Joensuu H, Kankaanranta L, Sepälä T, Auterinen I, Kallio M, Kulvik M, Laakso J, Vähätalo J, Kortesniemi M, Kotiluoto P, Seren T, Karila J, Brander A, Järviluoma E, Ryynänen P, Paetau A, Ruokonen I, Tenhunen M, Jääskeläinen J, Färkkila M, Savolainen S. Preliminary results of the first Finnish BPA-based BNCT trial on primary glioblastoma. In Research and Development in Neutron Capture Therapy, Sauerwein W, Moss R, Wittig A (eds). Monduzzi: Bologna, 2002; 1093-1098.
14. Capala J, Sköld K, Stensam BH, Munck af Rosenschöld PM, Giusti V, Persson C, Wallin E, Brun A, Carlsson J, Salford L, Ceberg C, Persson B, Pelletieri L, Henriksson R. Clinical BNCT studies in Sweden. In Research and Development in Neutron Capture Therapy, Sauerwein W, Moss R, Wittig A (eds). Monduzzi: Bologna, 2002; 1101-1106.
15. Burian J, Marek M, Rataj J, Flibor S, Rejchrt J, Viererbl L, Sus F, Honova H, Petruzelka L, Prokes K, Tovarys F, Dbaly V, Benes V, Kozler P, Honzatko J, Tomandl I, Mares V, Syrucek M. Report on the first patient group of the phase I BNCT trial at the LVR-15 reactor. In Research and Development in Neutron Capture Therapy, Sauerwein W, Moss R, Wittig A (eds). Monduzzi: Bologna, 2002; 1107-1112.
16. Wittig A, Hideghéty K, Paquis P, Heimans J, Vos M, Goetz C, Haselsberger K, Grochulla F, Moss R, Morissey J, Bourhis-Martin E, Rassow J, Stecher-Rasmussen F, Turowski B, Wiestler M, devries MJ, Frankhauser H, Gabel D, Sauerwein W. Current clinical results of the EORTC-study 11961. In Research and Development in Neutron Capture Therapy, Sauerwein W, Moss R, Wittig A (eds). Monduzzi: Bologna, 2002; 1117-1122.
17. Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat. Res. 1999; 151: 1-18.
18. Probst TU. Methods for boron analysis in boron neutron capture therapy (BNCT). A review. Fresenius J. Anal. Chem. 1999; 364: 391-403.
19. Mauri PL, Basilico F, Pietta PG, Pasini E, Monti D, Sauerwein W. New approach for the detection of BSH and its metabolites using capillary electrophoresis and electrospray ionization mass spectrometry. J. Chromatogr. B 2003; 788: 9-16.
20. af Rosenschold PMM, Verbakel WFAR, Ceberg CP, Stecher-Rasmussen F, Persson BRR. Toward clinical application of prompt gamma spectroscopy for in vivo monitoring of boron uptake in boron neutron capture therapy. Med. Phys. 2001; 28: 787-795.
21. Imahori Y, Ueda S, Ohmori Y, Kusuki T, Ono K, Fujii R, Ido T. Fluorine-18 labeled fluoroboronophenylalanine PET in patients with glioma. J. Nucl. Med. 1998; 39: 325-333.
22. Nichols TL, Kabalka GW, Miller LF, Khan MK, Smith GT. Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography. Med. Phys. 2002; 29: 2351-2358.
23. Kabalka GW, Nichols TL, Smith GT, Miller LF, Khan MK, Busse PM. The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. J. Neuro-oncol. 2003; 62: 187-195.
24. 19F-BPA in a mouse melanoma model. In Advances in Neutron Capture Therapy volume II, Chemistry and Biology, Larsson B, Crawford J, Weinreich R (eds). Elsevier: Amsterdam, 1997; 632-639.
25. Zuo CS, Prasad PV, Busse P, Tang L, Zamenhof RG. Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy. Med. Phys. 1999; 26: 1230-1236.
26. 10B-carrier, L-p boronophenylalanine-fructose complex, BPA-F: phantom studies at 1.5 and 3.O T. Phys. Med. Biol. 2003; 48: 1027-1039.
27. 11B nuclear magnetic resonance studies of the interaction of borocaptate sodium with serum albumin. Biochem. Pharmac. 1995; 49: 625-632.
28. Kabalka GW, Davis M, Bendel P. Boron-11 MRI and MRS of intact animals infused with a boron neutron capture therapy agent. Magn. Reson. Med. 1988; 8: 231-237.
29. Bendel P, Frantz A, Zilberstein J, Kabalka GW, Salomon Y. Boron-11 NMR of borocaptate: relaxation and in vivo detection in melanoma-bearing mice. Magn. Reson. Med. 1998; 39: 439-447.
30. Monoi H. Nuclear magnetic resonance of ions with quadrupole nuclei in aqueous heterogeneous systems: basic theory and applications. Rev. Magn. Reson. Med. 1986; 1: 73-122.
31. Yoshino K, Mishima Y, Kimura M, Hiratsuka J, Mori Y, Ito S, Kakihana H. Capture of p-boronophenylalanine in malignant melanoma cells by complex formation with melanin monomers, DOPA, DHI and DHICA. In Advances in Neutron Capture Therapy Volume II, Chemistry and Biology Larsson B, Crawford J, Weinreich R (eds). Elsevier: Amsterdam, 1997; 234-238.
32. Yamamoto Y, Takamatsu S, Nakamura H. Boron-11 NMR of boron compounds in the presence of cancer cells. J. Magn. Res. Ser. B. 1993; 101: 198-200.
33. Panov V, Salomon Y, Kabalka GW, Bendel P. Uptake and washout of borocaptate sodium and borono-phenylalanine in cultured melanoma cells: a multi-nuclear NMR study. Radiat. Res. 2000; 154: 104-112.
34. 11B magnetic resonance spectroscopy. Int. J. Radiat. Biol. 1996; 70: 587-592.
35. 2 relaxation and its application to boron-11 NMR imaging of a BNCT agent in an intact rat. J. Magn. Reson. 1990; 88: 369-375.
36. 11B MRI. Magn. Reson. Med. 1995; 34: 48-56.
37. Glover GH, Pauly JM, Bradshaw KM. Boron-11 imaging with a three-dimensional reconstruction method. J. Magn. Reson. Imag. 1992; 2: 47-52.
38. T regime. J. Magn. Reson. 1997; 129: 10-18.
39. 10B MRI. Magn. Reson. Med. 2001; 46: 13-17.
40. 10B NMR. Med. Phys. 2001; 28: 178-193.
41. De Luca F, Campanella R, Bifone A, Maraviglia B. Boron-10 double resonance spatial NMR detection. Chem. Phys. Lett. 1991; 186: 303-306.
42. 10B double resonance. Magn. Reson. Med 1994; 32: 170-174.
43. Bendel P. Lineshape and relaxation of spins I = 1/2 coupled to S = 3. Application to selective detection of protons attached to Boron-10. J. Magn. Reson. Ser. A 1995; 117: 143-149.
44. Bendel P, Baram A. Line narrowing of I = 1/2 spins coupled to quadrupolar nuclei in liquids: effects of weak decoupling fields. J. Magn. Res. 1999; 141: 121-132.
45. 10B MRI. In Research and Development in Neutron Capture Therapy, Sauerwein W, Moss R, Wittig A (eds). Monduzzi: Bologna, 2002; 877-880.
46. Yoshino K, Nakajima R, Takaoka A, Mori Y, Kakihana H, Mishima Y, Ichihashi M. Determination of released boric acid in vivo after p-boronophenylalanine administration into melanoma bearing subjects. In Advances in Neutron Capture Therapy Volume II, Chemistry and Biology, Larsson B, Crawford J, Weinreich R (eds). Elsevier: Amsterdam, 1997; 334-338.
47. Elhanati G, Salomon Y, Bendel P. Significant differences in the retention of the borocaptate monomer (BSH) and dimer (BSSB) in malignant cells. Cancer Lett. 2001; 172: 127-132.